Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy

Anti-Cancer Drugs

Volumn 21, Issue 1, 2010, Pages 89-93

  Saji, Hisashi ^a   Tsuboi, Masahiro ^a   Matsubayashi, Jun ^a   Miyajima, Kuniharu ^a   Shimada, Yoshihisa ^a   Imai, Kentaro ^a   Kato, Yasubumi ^a   Usuda, Jitsuo ^a   Kajiwara, Naohiro ^a   Uchida, Osamu ^a   Ohira, Tatsuo ^a   Hirano, Takashi ^a   Mukai, Kiyoshi ^a   Kato, Harubumi ^a   Ikeda, Norihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Large cell neuroendocrine carcinoma; Perioperative adjuvant chemotherapy; Prognostic factor

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; PACLITAXEL; UFT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG CARCINOMA; LUNG LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG LOBECTOMY; MALE; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PEROPERATIVE CARE; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PERIOPERATIVE CARE; PNEUMONECTOMY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 74349105477     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328330fd79     Document Type: Article

References (27)

1. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15:529-553.
2. Travis WD, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors, in World Health Organization International Histological Classification of Tumors. Berlin: Springer Verlag; 1999.
3. Dresler CM, Ritter JH, Patterson GA, Ross E, Bailey MS, Wick MR. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 1997; 63:180-185.
4. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22:934-944.
5. Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002; 124:285-292.
6. Paci M, Cavazza A, Annessi V, Putrino I, Ferrari G, De Franco S, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004; 77:1163-1167.
7. Doddoli C, Barlesi F, Chetaille B, Garbe L, Thomas P, Giudicelli R, et al. Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery. Ann Thorac Surg 2004; 77:1168-1172.
8. Filosso PL, Ruffini E, Oliaro A, Rena O, Casadio C, Mancuso M, et al. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J Thorac Cardiovasc Surg 2005; 129:819-824.
9. Battafarano RJ, Fernandez FG, Ritter J, Meyers BF, Guthrie TJ, Cooper JD, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130:166-172.
10. Veronesi G, Morandi U, Alloisio M, Terzi A, Cardillo G, Filosso P, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 2006; 53:111-115.
11. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006; 24:70-76.
12. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001; 91:1992-2000.
13. Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA, Miller JI. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001; 119:14-18.
14. Zacharias J, Nicholson AG, Ladas GP, Goldstraw P. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg 2003; 75:348-352.
15. Sobin L,Wittekind C. International union against cancer: TNM classification of malignant tumors. New York: Wiley-Liss; 1997.
16. Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006; 82:1802-1807.
17. Garcia-Yuste M, Matilla JM, Alvarez-Gago T, Duque JL, Heras F, Cerezal LJ, et al. Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Ann Thorac Surg 2000; 70:258-263.
18. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005; 23:8774-8785.
19. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360. (Pubitemid 38101630)
20. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-2597. (Pubitemid 41007845)
21. Strauss GM, Herndon J, Maddaus MA. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B protocol 9633 [abstract 7007]. J Clin Oncol 2006; 24:365S.
22. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer [Adjuvant Navelbine International Trialist Association (ANITA)]: a randomised controlled trial. Lancet Oncol 2006; 7:719-727.
23. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552-3559.
24. Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005; 49:217-223.
25. Hiroshima K, Iyoda A, Shibuya K, Haga Y, Toyozaki T, Iizasa T, et al. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer 2004; 100:1190-1198. (Pubitemid 38325947)
26. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996; 62: 798-809; discussion 809-810.
27. Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996; 148:1531-1541.